Apixer-2.5 Tablet

Apixaban 2.5 mg Tablets — Direct Oral Anticoagulant (DOAC) Therapy

📱 WhatsApp Enquiry📞 Call: +919041677932

About Apixer-2.5 Tablet

Apixer-2.5 Tablet contains Apixaban 2.5 mg, a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa in the coagulation cascade. The 2.5 mg twice-daily strength is used for venous thromboembolism (VTE) prophylaxis after hip or knee replacement surgery, for extended VTE prevention, and for AF stroke prophylaxis in selected high-risk elderly patients meeting dose-reduction criteria.

DOACs have largely replaced warfarin in modern anticoagulation practice because of fixed dosing, no routine monitoring, fewer food and drug interactions, and a more favourable bleeding profile — particularly lower intracranial haemorrhage risk. Apixaban specifically has the lowest major bleeding rate among the DOAC class in head-to-head trials.

Apixer-2.5 is manufactured by Trumac Healthcare under WHO-GMP conditions and is available for monopoly-based PCD pharma franchise and third-party manufacturing — a high-margin cardiology SKU with growing prescription demand.

Indications

• Prophylaxis of VTE after hip or knee replacement surgery
• Extended VTE prophylaxis (after initial 6 months of treatment)
• Stroke and systemic embolism prevention in non-valvular AF (dose-reduction criteria: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL — any two of these)
• Secondary prevention of recurrent VTE

Mechanism of Action

Apixaban is a highly selective, reversible direct inhibitor of free and clot-bound coagulation Factor Xa. By inhibiting Factor Xa, Apixaban prevents the conversion of prothrombin to thrombin, suppresses fibrin formation, and reduces thrombus growth and propagation — without directly affecting platelet aggregation.

Dosage & Administration

VTE prophylaxis after hip/knee replacement: 2.5 mg twice daily for 12–35 days. Stroke prevention in AF (dose-reduction criteria met): 2.5 mg twice daily. Extended VTE prevention: 2.5 mg twice daily. Swallow with or without food.

Side Effects

Bleeding (most common: epistaxis, GI bleeding, haematuria, easy bruising). Anaemia, nausea. Rare: major bleeding, intracranial haemorrhage, hypersensitivity reactions. Compared with warfarin: lower intracranial bleeding rate.

Contraindications & Precautions

Active clinically significant bleeding. Hepatic disease with coagulopathy. Concomitant strong CYP3A4 + P-gp inhibitors (ketoconazole, ritonavir) or inducers (rifampicin). Pregnancy and breastfeeding. Prosthetic heart valves. Recent intracranial/spinal surgery. Severe renal impairment (CrCl < 15 mL/min).

Storage

Store below 30 °C in a dry place, protected from light and moisture.

Frequently Asked Questions

Related Products

• Apixer-5 Tablet — Apixaban 5 mg
• Atorship-10 Tablet — Atorvastatin Calcium 10 mg
• Amrocip-500 Tablet — Ciprofloxacin Hydrochloride 500 mg